Malignancy
Conditions
Interventions
Day1. The administration of the 5HT3Receptor antagonist and aprepitant 125mg/day, extracellular fluid 500ml+MgSO4 8mmol before CDDP. And, extracellular fluid 500ml again after CDDP. Day2.3 Oral a
Sponsors
Kansai Medical University Hirakata Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically or cytologically proven malignant tumors 2) select the combination therapy, including cisplatin as first line 3) over 20 years of age 4) ECOG PS 0,1 5) Adequate organ function WBC more than 3,500/mm3 NETRO more than 2,000/mm3 PLT more than 100,000mm3 Hb more than 9.0g/dL AST, ALT under 100IU/L T-BiL under 2.0mg/dL Cre under 1.0mg/dL Ccr(Cockcroft-Gault)more than 50mL/min SpO2 more than 90% 6) consent is obtained in writing for participation in this study
Exclusion criteria
Exclusion criteria: 1)History of administration platinum-based chemotherapy 2)With Serious infectious disease 3)Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 4) A history or cardiac dysfunction 5)With massive pleural effusion or ascites 6)History of serious disease condition 7)History of drug allergy 8) The hope of pregnancy or cases that may pregnant women, pregnant woman 9) Cases of breast-feeding 10) Cases attending physician was deemed inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Response grade0 rate of creatinin | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion rate, Complete Control rate, adverse events, total control rate | — |
Countries
Japan
Contacts
Public ContactMaiko Niki
Kansai Medical University Hirakata Hospital Thoracic oncology
Outcome results
None listed